北京若生智能科技有限公司
Drug Database
AT

atorvastatin strontium (Newvast)

✓ Approved

Hanmi Pharmaceutical · HMGCR · 小分子

什么是 atorvastatin strontium？

atorvastatin strontium 是一种小分子，由Hanmi Pharmaceutical研发。该药已获批，用于治疗相关适应症，给药途径：Oral (PO)。

药物档案

商品名Newvast
公司Hanmi Pharmaceutical
药物类别小分子
分子靶点HMGCR
给药途径Oral (PO)
状态Approved
来源： ClinicalTrials.gov, Hanmi Pharmaceutical

作用机制

分子靶点

atorvastatin strontium 作用于 1 个分子靶点：

HMGCR3-hydroxy-3-methylglutaryl-CoA reductase (LDLCQ3, LGMDR28)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

atorvastatin strontium 针对 2 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Metabolism and nutrition disordersHypercholesterolaemia✓ Approved
Metabolism and nutrition disordersHyperlipidaemia✓ Approved

相关研究文献

PubMedGels (Basel, Switzerland)2026-10-26

Recent Advances in Novel Adsorbents Prepared by the Sol-Gel Method for the Removal of Uranium and Strontium from Radioactive Wastewater: A Review.

Jiang Jiayi J, Zhao Jiaxue J, Chen Miaoling M, Chen Diyun D et al.

Uranium- and strontium-containing wastewater from nuclear industries poses a threat to the environment and human health. The sol-gel method, with its tunable composition and synthetic flexibility, is widely used to fabricate novel and high-performance adsorbents. This review covers recent progress in the sol-gel fabrication of UO22+ and Sr2+ adsorbents, including both inorganic and organic-inorganic hybrid materials. Reported adsorption capacities typically range from about 40 to 670 mg/g for UO22+ and from about 40 to 370 mg/g for Sr2+, with a few systems achieving even higher values under optimized conditions. Titanates and titanosilicates exhibit outstanding selectivity toward Sr2+, whereas phosphate-based materials and amidoxime-functionalized hybrids show strong affinity for UO22+. However, practical application is still hampered by high precursor costs, poor shapeability, limited long-term stability, harsh regeneration conditions, and interference from coexisting ions. Future efforts should focus on low-cost materials and shaping processes to promote the engineering applications of tailored materials via the sol-gel method.

PMID 42929925
阅读全文 →
PubMedRapid communications in mass spectrometry : RCM2026-10-26

TIMS Techniques for Measuring Strontium Isotope Ratios in Apatite Grains and Application to Igneous Rock Petrology.

Neto Carla C, de Morisson Valeriano Claudio C, Paravidini Gabriel G, Bruno Henrique H et al.

This study evaluates the potential of Sr isotopic compositions in apatite grains from magmatic rocks as a proxy for initial 87Sr/86Sr ratios, addressing the need for alternative approaches to conventional whole-rock analyses in isotopic studies of granitoid systems. Chemical and spectrometric procedures were optimized and validated for the determination of Sr isotopic ratios in apatite by TIMS. Three representative samples from the Ribeira Orogen, Brazil, were selected, and apatite Sr isotopic compositions were compared with initial whole-rock 87Sr/86Sr ratios calculated from U-Pb zircon crystallization ages, whole-rock isotopic ratios, and Rb and Sr concentrations. The reliability of the analytical approach was evaluated using the EN-1 and Durango apatite reference materials. Apatite grains yielded Sr concentrations ranging from 80 to 950 μg g-1, with total Sr masses between 0.5 and 50 ng. Comparisons between apatite-derived and whole-rock initial 87Sr/86Sr ratios show isotopic variability below 0.05%, indicating high analytical precision. Validation results demonstrate consistent agreement between methods, with uncertainties within 0.5%. The proposed TIMS-based method for Sr isotope analysis in apatite grains provides a potential approach for investigating the initial Sr isotopic compositions of granitoid magmatic systems. This approach represents a cost-effective and time-efficient alternative to traditional whole-rock analyses, with strong potential for large-scale isotopic applications in orogenic terrains.

PMID 42928975
阅读全文 →
PubMedDrug design, development and therapy2026-10-25

Steady-State Pharmacokinetic Drug-Drug Interaction Study of Zastaprazan, a Novel Potassium-Competitive Acid Blocker, and Atorvastatin in Healthy Participants.

Yang A-Young AY, Kim Hongsock H, Yoo Hyounggyoon H, Lee Yil-Seob YS et al.

Zastaprazan is a novel potassium-competitive acid blocker with CYP3A-mediated metabolism, whereas atorvastatin undergoes CYP3A4- and transporter-mediated disposition. Because these drugs may be co-administered and their net interaction cannot be inferred from shared metabolic pathways alone, this study evaluated their steady-state pharmacokinetic drug-drug interaction. This open-label, fixed-sequence, three-period, multiple-dose study included healthy Korean men. Participants received atorvastatin 40 mg once daily, zastaprazan 20 mg once daily, and concomitant atorvastatin and zastaprazan, each for 5 consecutive days, under steady-state conditions. Plasma concentrations of zastaprazan, atorvastatin, and 2-hydroxyatorvastatin were measured, and geometric mean ratios (GMRs) with 90% confidence intervals (CIs) were calculated for C max,ss and AUC τ,ss. Twenty-four healthy Korean men received at least one dose of a study drug, and 22 were included in the pharmacokinetic analysis. Atorvastatin decreased zastaprazan C max,ss by approximately 26% (GMR, 0.740; 90% CI, 0.655-0.836), whereas AUC τ,ss was preserved (GMR, 1.054; 90% CI, 0.927-1.198). Zastaprazan did not meaningfully alter atorvastatin exposure (C max,ss GMR, 0.982; 90% CI, 0.806-1.195; AUC τ,ss GMR, 1.029; 90% CI, 0.944-1.122). The AUC τ,ss of 2-hydroxyatorvastatin showed a modest decrease (GMR, 0.940; 90% CI, 0.889-0.994) that remained within the predefined conventional reference range. Co-administration was generally well tolerated, with no serious adverse events or adverse event-related discontinuations. Zastaprazan did not meaningfully alter atorvastatin C max,ss or AUC τ,ss under the studied conditions. Although atorvastatin reduced zastaprazan C max,ss, total exposure was preserved, a pattern consistent with altered absorption kinetics without establishing a specific mechanism. The pharmacodynamic significance of the lower zastaprazan C max,ss remains uncertain because intragastric pH was not measured. These pharmacokinetic findings do not suggest a need for atorvastatin dose adjustment under the studied conditions.

PMID 42921573
阅读全文 →
PubMedPeerJ2026-10-25

Effectiveness and safety of atorvastatin/ ezetimibe fixed-dose combination in hypercholesterolemia: a systematic review and network meta-analysis.

Qian Juying J, Zhang Xingxin X, Li Qing Q, Chen Sisi S

Many patients fail to achieve low-density lipoprotein cholesterol (LDL-C) targets with statin monotherapy, calling for a combination of statins and ezetimibe. This systematic review and network meta-analysis evaluated the comparative effectiveness and safety of atorvastatin monotherapy, atorvastatin/ezetimibe free-equivalent combination (AS/EZ FEC), and fixed-dose combination (AS/EZ FDC) in patients with hypercholesterolemia. Randomized controlled trials were retrieved from electronic databases. Primary outcomes were the percentage change in LDL-C from baseline and LDL-C goal attainment, analyzed using mean difference (MD) and risk ratio (RR) with 95% confidence intervals (CI). Treatments were ranked via surface under the cumulative ranking curve (SUCRA). The two combination therapies were compared to AS alone for their safety profiles and tolerability. Forty-six trials (n = 10,567) were included. AS/EZ FDC reduced LDL-C more than AS alone (MD -13.94%, 95% CI [-18.90% to -9.10%]), with similar results for AS/EZ FEC (MD -12.41%, 95% CI [-14.61% to -10.22%]). SUCRA rankings for LDL-C reduction were FDC (86.2%), FEC (63.8%), and AS (0.0%). For LDL-C goal attainment, the RR was 1.87 (95% CI [1.47-2.39]) for FEC vs. monotherapy, 1.80 (95% CI [0.85-3.81]) for FDC vs. monotherapy. No significant differences in safety profiles were observed between treatments. AS/EZ combination therapies provide greater improvements in LDL-C reduction and goal attainment compared with AS monotherapy, with FDC ranking highest in LDL-C reduction. Treatment with AS/EZ FEC or FDC did not increase the risk of adverse events compared to AS monotherapy and was well tolerated. These findings support FDC use when intensive LDL-C lowering is required.

PMID 42927391
阅读全文 →
PubMedAnalytical methods : advancing methods and applications2026-10-25

Hydrazone-derived PET/CHEF fluorescent probes for sensitive detection of cesium and strontium in real samples.

Udhayakumar Raja R, Kumar Rajesh R, Velmathi Sivan S

In this study, two hydrazone-based probes, NSP ((E)-5-(diethylamino)-2-((2-(2,4-dinitrophenyl)hydrazineylidene)methyl)phenol) and NFH ((E)-N'-(4-(diethylamino)-2-hydroxybenzylidene)furan-2-carbohydrazide), were developed and synthesized for the specific detection of Cs+ and Sr2+ ions, respectively. Both probes were very sensitive, with low detection limits of 2.4 nM for Cs+ and 22 nM for Sr2+, along with high selectivity over other metal ions. The binding constant is 4.8 × 107 M-1 for NSP-Cs+ and 6.4 × 105 M-1 for NFH-Sr2+. Job's plot analysis confirmed a 1 : 1 binding stoichiometry between the probes and their corresponding metal ions. The NSP- and NFH-functionalized cotton swabs exhibit excellent stability, highlighting their potential for portable and on-site detection. Complementarily, their efficacy was demonstrated in actual samples, including water, soil, and vegetable matrices, achieving excellent recovery results.

PMID 42924537
阅读全文 →
PubMedSmall science2026-10-25

Non-Equimolar High-Entropy Spinel Oxides as Anode Materials for a Direct Ammonia-Fed Solid Oxide Fuel Cell.

Elmutasim Omer O, Pinczes Maxwell P MP, Dhawale Dattatray S DS, Giddey Sarbjit S et al.

High-entropy oxides (HEOs) have emerged as promising electrocatalysts owing to their unique cocktail effect, which enables synergistic multielement interactions, leading to enhanced catalytic activity. In this work, three novel non-equimolar high-entropy spinel ferrites-based materials, (M0.3Ni0.21Cu0.21Co0.14Mn0.14)Fe2O4 (M = Fe, Mg, or Zn)-Gd0.1Ce0.9O1.95 (GDC), have been adopted as anodes for direct-ammonia solid oxide fuel cells (DA-SOFCs). Synchrotron-based X-ray absorption spectroscopy (XAS) and micro-computed tomography (Micro-CT) were employed, alongside X-ray diffraction (XRD), inductively coupled plasma-optical emission spectroscopy (ICP-OES), scanning electron microscopy (SEM), scanning transmission electron microscopy with energy-dispersive X-ray spectroscopy (STEM-EDX), X-ray photoelectron spectroscopy (XPS), and Raman spectroscopy, for comprehensive characterization. The XRD analysis showed that the HEO(Zn) and HEO(Mg) samples exhibited a single-phase high-entropy spinel ferrite, whereas the d-HEO(Fe) displayed a dual-phase structure comprising a predominant spinel phase (90.9 wt%) and a minor hematite (Fe2O3) phase. The HEO samples were treated in a reducing atmosphere to form a composite with a monometallic Fe phase (>82.4 wt%) and FeNiCu alloy. Extended X-ray absorption fine structure spectroscopy (EXAFS) analysis revealed that the Fe3+, Cu2+, Ni2+, and Co2+ cations are distributed between the octahedral and tetrahedral coordination environments within d-HEO(Fe) sample, while the Mn3+ ions are located at the octahedral sites. The lanthanum strontium gallium magnesium oxide (LSGM) electrolyte-supported cell with a d-HEO(Fe) anode achieved the highest peak power density (PPD) of nearly 382.0 mW/cm2 at 850 °C, whereas the SOFCs with HEO(Zn) and HEO(Mg) anodes delivered lower PPD values of 218.3 and 195.7 mW/cm2, respectively. Notably, the cell with the d-HEO(Fe) anode demonstrated excellent durability for over 75 h at 800 °C, with only 3.16% voltage degradation. Density functional theory (DFT) computations were carried out to scrutinize the NH3 decomposition mechanism on the Fe(110) surface, which represents the reduced HEO anode, and were benchmarked against those on the Ni(111) surface. Interestingly, the formation of the N2* species via recombination of N* atoms is identified as the rate-controlling step for NH3 cracking on Fe(110) and Ni(111), exhibiting the highest activation barriers of 2.43 and 1.63 eV, respectively, among all elementary steps considered.

PMID 42923066
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多atorvastatin strontium